Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2022-03-08 00:00:00 ET · period of report 2022-03-02 · accession 0001209191-22-016929 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-08 | 2022-03-02 | VIR | Friedl-Naderer Johanna | Chief Business Off, Gbl | A - Grant | $0.00 | +90.0K | 90.0K | New | $0 |
| D | 2022-03-08 | 2022-03-02 | VIR | Friedl-Naderer Johanna | Chief Business Off, Gbl | A - Grant | $0.00 | +45.0K | 45.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-02 | A | A | 90,000 | $0.00 | 90,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-02 | A | A | 45,000 | $0.00 | 45,000 | D | $24.13 · — to 2032-03-01 | 45,000 Common Stock | (F2) 25% of the shares subject to the stock option vest and become exercisable on March 2, 2023, and the remainder vest in 36 equal monthly installments thereafter. |